How IRP and MFN-Style Pressures Are Quietly Redrawing Pricing Strategy in Europe

Strategic insights for pharma leaders navigating pricing turbulence in 2025–26

For decades, International Reference Pricing (IRP) where countries set or cap medicine prices based on prices in a basket of other countries has been a cornerstone of European price regulation. It has delivered short-term containment and a broadly stable framework, but its systemic effects have long strategic implications that go beyond simple cost control. Meanwhile, the rise of Most-Favored-Nation (MFN)-style pricing pressures most visibly coming from the United States has injected fresh uncertainty into European pricing dynamics, reshaping launch strategies and pricing playbooks. (ScienceDirect)

In 2026, senior executives must recognise that the era of predictable, list-price-dominated pricing regimes in Europe is giving way to a more interconnected, spillover-driven environment with consequences for access, launch sequencing, and global pricing corridors.

What I Mean by IRP vs. “MFN-Style” Pressures

IRP in Europe refers to statutory processes where policymakers set maximum or reference prices based on other countries’ prices often using the lowest, median, or average price from a defined basket. Nearly all major EU nations employ some form of IRP as part of their pricing toolbox. (Wikipedia)

True Most-Favored-Nation (MFN) pricing where a country caps its price at the lowest price paid anywhere among a set of comparator economies is rare in Europe itself. What we’re seeing today is pressure influenced by MFN thinking particularly driven by external forces such as the new U.S. MFN proposal which is forcing pharma companies and European policymakers to rethink their strategic calculus. (valueinhealthjournal.com)

1) IRP’s Structural Effect: Price Convergence Anchored to Big Markets

European IRP regimes have driven price convergence around large, high-income markets like Germany and France. Rather than creating a race to the bottom across all markets, the strongest empirical analyses show that list prices across IRP countries tend to align with those of the largest reference economies, while smaller markets rely on confidential discounts to make net prices sustainable. (ScienceDirect)

This convergence is not inherently about lowering costs everywhere; it’s about leveraging the price anchors set by stronger economies to contain budget impact. Confidential discounts and managed entry agreements are deployed to preserve access without distorting net pricing too aggressively but these mechanisms also weaken price transparency. (ScienceDirect)

2) Policy Shifts in IRP Methodology: Flexibility Over Lowest-Price Fixation

Recent IRP developments show a subtle shift in methodological approaches: fewer countries are adopting the pure lowest-price rule in their IRP basket, opting instead for averages, medians, or more nuanced formulae. This reflects an effort to balance price control with market sustainability, particularly amid supply constraints. (pharmaceutical-technology.com)

This evolution signals that simple IRP mechanics are no longer seen as an optimal long-term strategy. Policymakers increasingly recognise the risk that overly rigid IRP formulas can exacerbate launch delays and access inequities, pushing them to refine how reference baskets are constructed and recalculated. (pharmaceutical-technology.com)

3) External MFN Pressures: Strategic Disruption From Beyond Europe

The U.S. MFN pricing proposal, designed to align U.S. prices with the lowest among a set of OECD countries, has sparked strategic recalibration globally. Although this is not a European regulation, its spillover effects on pricing strategy and launch sequencing are real. (pharmexec.com)

Pharma companies are currently grappling with the risk that low list prices in Europe could become reference anchors under an MFN regime elsewhere (notably the U.S.). As a result, manufacturers may attempt to protect global price corridors by:

• Pursuing higher list prices in Europe,

• Increasing reliance on confidential net pricing to maintain access, and

• Reconsidering launch timing in traditionally lower-priced markets. (Remap Consulting)

This dynamic is already affecting European policy debates and internal strategies, especially in markets with strict list-price referencing regimes.

Strategic Implications for Pharma Leadership

These intertwined pressures evolving IRP methodologies and external MFN-style forces mean that a global pricing strategy cannot be managed in silos. Executives will need to rethink three core levers:

➤ Launch Sequencing and Portfolio Timing

Delaying entry into low-price countries may be strategically rational if those prices threaten global reference benchmarks. But this carries market access risks and can erode patient access and long-term competitiveness.

➤ List Price vs. Net Price Strategy

Maintaining higher list prices while delivering sustainable net prices via confidential agreements is no longer just a pricing tactic; it’s a defensive strategy against spillover risk. However, this increases complexity in payer negotiations and economic evaluations. Furthermore, it is unclear whether this is a sustainable strategy. If the US government does indeed request information on net prices, then the net price strategy will be ineffective.

➤ Engagement With Policymakers

With IRP all but entrenched in Europe and external MFN pressure rising, proactive engagement with clear evidence on access impacts and innovation incentives is essential. European regulators are wary of unintended consequences like delayed access or shrinking innovation incentives. (ScienceDirect)

What to Watch Next

In 2026, three indicators will signal strategic direction:

1. IRP formula refinement in major markets like France, Germany, and Italy.

2. European responses to external MFN pressure especially in ongoing EU pharmaceutical policy negotiations.

3. Data transparency initiatives that force clearer reporting of net prices versus list prices.

Closing Thought

Europe’s pricing landscape is no longer defined by static reference rules. It is being reshaped by the interplay of domestic price methodologies, global policy disruptions, and strategic corporate responses. Pharma leaders who master both the mechanics and the strategic ramifications will be best positioned to navigate the next wave of pricing evolution.

Selected Sources

• International reference pricing converges prices around larger countries and may delay access without sustainable reductions. (ScienceDirect)

• Countries are shifting IRP methodology away from pure lowest-price formulas. (pharmaceutical-technology.com)

• U.S. MFN pricing proposals create strategic spillover risks for European pricing. (pharmexec.com)

• MFN pressures are affecting list pricing and launch timing strategies. (Remap Consulting)